UA-Axial, A study of the efficacy, safety, and tolerability of AB-2004 in a 13 to 17 year old ASD Population
Project Description:
Research has shown the gut flora of autistic children is different as compared to those children who are not on the autism spectrum. It is possible certain bacteria in the gut produce substances that may reach the brain resulting in characteristics of autism.
We are researching an experimental treatment, AB-2004, which is designed to adsorb these substances to reduce their levels circulating in the blood stream. By lowering the levels of these substances, we hope to improve characteristics such as irritability associated with autism. This study aims to find the most effective dose of AB-2004 in 13- to 17-year-old adolescents on the autism spectrum.
Core Function(s):
Performing Research or Evaluation
Area of Emphasis
Health-Related Activities
Target Audience:
Adults with Disabilities, Children/Adolescents with Disabilities/SHCN
Unserved or Under-served Populations:
Racial or Ethnic Minorities, Specific Groups
Primary Target Audience Geographic Descriptor:
State
COVID-19 Related Data:
N/A